Compare AbCellera Biologics Inc (ABCL) vs Zoom Video Communications, Inc. (ZM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Zoom Video Communications, Inc. — how do they compare? AbCellera Biologics Inc trades at $10.35 (market cap $2.99B), while Zoom Video Communications, Inc. trades at $106.64 (market cap $31.10B). The key difference: Zoom Video Communications, Inc. is far larger — about 10.4× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Zoom Video Communications, Inc. nearer its low. Which is the better fit depends on your goals.
| ABCL | ZM | |
|---|---|---|
Market Cap | $2.99B | $31.10B |
Sector | Health | Technology |
52-Week High | $9.76 | $111.88 |
52-Week Low | $2.78 | $69.96 |
Enterprise Value | $2.58B | $23.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $10.34, up 10.71% on positive Phase 2 trial results for its menopause drug ABCL635, which showed 83% reduction in hot flashes. Despite negative profitability metrics, the stock maintains strong analyst support with 91.7% buy ratings and a $15.50 consensus target. Technical indicators show bullish momentum with the price near resistance at $11, though RSI levels suggest overbought conditions.
The outlook remains speculative given ongoing losses but is supported by promising clinical data and strategic partnerships. Key risks include drug development timelines, cash burn, and reliance on successful commercialization. Upside potential exists if ABCL635 advances successfully through regulatory phases.
Zoom Communications (ZM) trades at $104.70, down 2.33% today, with mixed technical signals showing bullish moving averages but overbought RSI levels. The company maintains strong profitability with 77.4% gross margins and 42% net income margin, though recent earnings show volatility with one miss in the last four quarters. Recent news highlights CEO and director stock sales totaling over $7 million in July-August 2026, while the company continues AI product development and APAC expansion.
Outlook remains cautiously optimistic with a $118.79 consensus price target representing 13% upside potential. Key opportunities include sustained profitability and AI-driven growth initiatives, while risks center on insider selling pressure and competitive threats in the video communications space. The stock faces near-term technical resistance at $107-$109 levels with support at $103-$105.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Zoom Video Communications, Inc.
Zoom Video Communications, Inc. develops a people-centric cloud service that transforms real-time collaboration experience. The Company offers unified meeting experience, a cloud service that provides a 3-in-1 meeting platform with HD video conferencing, mobility, and web meetings. Zoom Video Communications serves customers worldwide.
Read more on ZM →
